Colorectal cancer and mismatch repair-deficient disease
Research activity centers on metastatic colorectal cancer, colorectal adenocarcinoma, and localized colon cancer, with particular interest in dMMR and MSI-H populations.
- Immune checkpoint inhibition
- Neoadjuvant immunotherapy
- Watch-and-wait strategies
- Anti-PD1-resistant disease
Clinical questions also include disease control in localized and metastatic settings, with attention to organ preservation and response assessment.
Gastric and gastro-oesophageal adenocarcinoma
The sponsor is active in metastatic gastric cancer, metastatic gastric adenocarcinoma, and localized gastro-oesophageal junction disease, including tumors with PD-L1 expression and MSI-H biology.
- First-line immunotherapy combinations
- Chemotherapy backbones
- Microbiome-related treatment approaches
- Non-operative management
Interest extends to treatment selection in biomarker-defined gastric cancer and the use of response-driven strategies.
Pancreatic ductal adenocarcinoma
Another major area is locally advanced and metastatic pancreatic ductal adenocarcinoma, with studies focused on patients after induction treatment and in maintenance settings.
- Maintenance therapy
- Sequential treatment strategies
- Survival outcomes
- Antibiotic and microbiota exploration
Trial activity includes optimization of systemic therapy pathways for advanced pancreatic cancer.
Digestive neuroendocrine carcinomas
The sponsor also studies localized digestive neuroendocrine carcinomas, with a focus on resectable disease and postoperative recurrence risk.
- Neoadjuvant chemotherapy
- Relapse-free survival
- Localized resectable disease
This area reflects interest in perioperative treatment for uncommon gastrointestinal malignancies.
Targeted and immune-based gastrointestinal oncology
Across its portfolio, the sponsor works with nivolumab, ipilimumab, pembrolizumab, dostarlimab, bevacizumab, trifluridine/tipiracil, and FOLFOX– or FOLFIRI-based treatment platforms in gastrointestinal cancers.
- Biomarker-driven treatment selection
- Combination immunotherapy
- Maintenance treatment
- Toxicity management
Research spans advanced gastrointestinal tumors with emphasis on response, tolerability, and disease control.
